bb21217 Shows Encouraging Efficacy, Safety, and CAR T-Cell Expansion
By DocWire News Editors - Last Updated: April 27, 2023Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the safety and efficacy results of the CRB-402 trial, which evaluated bb21217 in patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Related Posts
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.